Physician profile
Henry Wu
NPI 1891795670
$3,644.12
in general payments reported to CMS, 2019-2025
30 companies · $902 in 2025
The $902 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $139 · 2021: $90.50 · 2022: $842 · 2023: $707 · 2024: $810 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,376 · Education: $43.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.38 |
| Education | $43.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $556.99 | 2019-2025 | Farxiga |
| Abbott Laboratories | $324.13 | 2024-2025 | Proclaim |
| Fresenius USA Marketing, INC. | $319.26 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $300.74 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $297.66 | 2020-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $278.58 | 2020-2024 | Acthar |
| Amgen INC. | $209.86 | 2019-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $178.23 | 2023-2025 | |
| Vifor Pharma, INC. | $154.37 | 2019-2025 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $135.10 | 2022-2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $123.29 | 2024-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $116.05 | 2022-2025 | Benlysta, Jesduvroq |
| Nxstage Medical, INC. | $90.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $78.36 | 2020-2025 | |
| Lilly USA, LLC | $64.53 | 2023-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $48.40 | 2025 | |
| Ardelyx, INC. | $48.29 | 2023-2025 | Ibsrela |
| Akebia Therapeutics INC | $46.63 | 2022 | |
| Kyowa Kirin, INC. | $36.73 | 2025 | |
| Mallinckrodt Enterprises LLC | $34.20 | 2019 | |
| Apellis Pharmaceuticals, INC. | $30.30 | 2025 | Empaveli |
| Novo Nordisk INC | $25.61 | 2025 | Ozempic |
| Merck Sharp & Dohme LLC | $22.63 | 2022 | |
| Daiichi Sankyo INC. | $21.61 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.68 | 2022 | |
| Opko Pharmaceuticals, LLC | $18.88 | 2022 | |
| Ani Pharmaceuticals, INC. | $17.70 | 2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.83 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $15.68 | 2022 | |
| Horizon Therapeutics Plc | $14.30 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.